Gerard Bruder, PhD
Professor of Clinical Psychology
Dr. Bruder directs the Psychophysiology Laboratory in the Cognitive Neuroscience Division of New York State Psychiatric Institute. His research uses electrophysiologic measures, such as quantitiative EEG and event-related brain potentials (ERPs), as well as cognitive tests to study neurocognitive function in patients with depressive, schizophrenic, or anxiety disorders.
He is the recipient of grants from the National Institute of Mental Health for studies in depressive disorders and schizophrenia. His research in depressive disorders has focused on the use of EEG, ERP, and neurocognitive measures of brain function and its relation to diagnostic subtypes and therapeutic response to antidepressant medications. He is also involved in electrophysiologic studies of brain activity in offspring of depressed patients who are at risk for depressive or anxiety disorders.
His research in schizophrenia at the Lieber Center for Schizophrenia Research has focused on studies using brain ERP and cognitive measures of working memory, recognition memory, and right-left brain asymmetry. He has also studied the genetic basis of working memory abilities.
The Psychophysiology Laboratory is also one of the few sites measuring brain potentials to olfactory stimuli in schizophrenia. He is Co-Investigator of studies of olfaction in individuals with emerging psychosis during the prodromal period, and of emotional reactions to odors in depression.
Dr. Bruder has been a member of the editorial board of the International Journal of Psychophysiology and Clinical EEG and Neuroscience. He has also served on multiple NIMH grant review groups.
Studies are using electrophysiologic (EEG and event-brain related potential) and behavioral measures to study neurophysiologic, cognitive, and olfactory function in depressive disorders and schizophrenia.
Current studies are being conducted in four areas: (1) examining the value of electrophysiologic (EEG, ERP) measures and tests of right-left brain asymmetry and neurocognitive function for predicting clinical responsiveness to antidepressants; (2) studies of working memory and recognition memory in schizophrenia using both brain ERPs and cognitive tests; (3) studies of olfactory function in schizophrenia and depression using ERP and behavioral measures; and (4) electrophysiologic studies of children at risk for depressive or anxiety disorders.